COQUITLAM, BC, Canada, Jan 19, 2021 (SEND2PRESS NEWSWIRE) Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results.
In addition to the French study, a team from the University of Novi Sad in Serbia has also reported promising preliminary findings from a small pilot trial administering Drink HRW tablets to patients hospitalized from COVID-19.
COQUITLAM, BC, Canada, Jan 19, 2021 (SEND2PRESS NEWSWIRE) Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results.
In addition to the French study, a team from the University of Novi Sad in Serbia has also reported promising preliminary findings from a small pilot trial administering Drink HRW tablets to patients hospitalized from COVID-19.
For food & supplement brands hoping 2021 might be the year the FDA unveils a long-awaited regulatory framework for CBD, its Jan 7 progress report citing the need for more safety data does not provide much encouragement, with the Council for Responsible Nutrition (CRN) blasting it as “nothing more than an end-of-Administration desk-clearing exercise.”
Psyched Wellness Ltd.: Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (
CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (the
Company or
Psyched ) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has shipped its first batch of Amanita Muscaria extract to its CRO partner to commence the Pre-Clinical trials.
The Company sent 108 grams of highly concentrated Amanita Muscaria extract to its CRO s lab to begin the first phase of its Pre-Clinical Trial. This first batch of Amanita extract will be used in a study to determine the Maximum Tolerated Dose (MTD). The goal of the study is to determine the highest dose of our extract that will not cause unacceptable side effects or an overt toxicity in a defined period. This is a key first step in determining the appropriate dosage for our future products.